Cangen Biotechnologies, Inc. And Olympus To Collaborate On Development Of High-Throughput Molecular Diagnostic Test For Lung Cancer
10/19/2005 5:09:48 PM
BETHESDA, Md.--(BUSINESS WIRE)--May 25, 2005--Cangen Biotechnologies, Inc. today announced a research collaboration with Olympus Corporation for the development of a hybrid DNA-based and protein-based diagnostic test for use in the detection of lung cancer. This collaboration will provide Cangen Biotechnologies with access to Olympus' microarray technology to enable the DNA-based portion of the test allowing high-throughput testing for lung cancer. Under the terms of the agreement, Olympus is responsible for refining and further developing its microarray technology in an effort to accommodate Cangen's development of the hybrid DNA-based and protein-based diagnostic test for the detection of lung cancer.
"We are excited about this opportunity to work in collaboration with Olympus in an effort to develop an accurate and cost-effective test to detect lung cancer in early stages," stated Chul So Moon, M.D., Ph.D., Chief Executive Officer and Chief Science Officer of Cangen Biotechnologies. "Such a test would enable the improvement of medical care for people all around the world," Dr. Moon added.
comments powered by